# ABT-301

Source: https://onco.cc/drugs/abt-301/  
OnCo record `abt-301` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ABT-301 is an experimental small-molecule drug from Anbogen Therapeutics in phase 2 trials for colorectal cancer, aimed at Histone deacetylases (HDAC).

## Summary

ABT-301 is a small-molecule drug developed by Anbogen Therapeutics. Its target is Histone deacetylases (HDAC). ClinicalTrials.gov describes the intervention as: ABT-301 is an oral histone deacetylase inhibitor (HDACi) administered in capsule form once daily (QD ±3 hours) or every 12 hours (Q12H ±3 hours, with at least 9 hours between doses) with water in 21-day treatment cycles. In Part 1 (dose-esc. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in colorectal cancer. The largest, NCT07244705, plans to enrol 66 participants with primary completion expected 2028-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: MPT0E028; Imofinostat
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: Small-molecule drug directed at Histone deacetylases (HDAC), as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of ABT-301: https://clinicaltrials.gov/search?intr=ABT-301

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- targets: [Histone deacetylases (HDAC)](https://onco.cc/targets/hdac/)
- trials: [A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC](https://onco.cc/trials/nct07244705/)
- companies: [Anbogen Therapeutics](https://onco.cc/companies/anbogen-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/abt-301.json